Predictive 3D In Vitro Models Should Make Research Easier- Not More Complicated
Human-relevant 3D in vitro models can provide valuable insights into drug safety, efficacy, and disease biology. Yet, establishing these physiologically relevant models internally often requires considerable time, specialist expertise, and laboratory resources.
Researchers must identify suitable cell sources, optimise cell aggregation and culture conditions, define quality-control criteria, validate functional performance, and demonstrate experimental reproducibility. Even after a workflow has been established, differences in cell lots, microtissue size, culture conditions, and operator handling can introduce variability and make results more difficult to interpret.
For drug discovery teams working under tight timelines, the challenge is therefore not simply gaining access to advanced biology. It is finding models that combine human-relevant predictivity with streamlined workflow integration – 3D models that can be implemented efficiently, scaled reliably, and applied with confidence across safety and efficacy studies.
InSphero’s assay-ready 3D InSight™ Microtissue portfolio, including liver, islet, and neural models, is designed to address this need. Pre-aggregated (1 microtissue/well) and quality-controlled microtissues are delivered directly in automation-compatible AkuraTM 96x or 384x Spheroid Microplate, reducing the need for researchers to build, optimise, and validate complex 3D in vitro models internally. This allows scientific teams to move more quickly into study design, compound testing, data analysis, and decision-making.
Standardized Microtissue Production for Scalable, Reliable Results
In pharmaceutical drug discovery, a predictive 3D in vitro model is only valuable when it delivers consistent performance across compounds, concentrations, plates, batches, and long-term studies. Variability in the model can impact biological response and make findings difficult to reproduce or compare over time.
InSphero’s established microtissue production processes are designed to achieve this consistency at scale. Microtissues are produced under controlled conditions to achieve uniformity in size, viability, and functionality, helping to reduce well-to-well and plate-to-plate variability.
Each production batch undergoes defined quality-control procedures to verify model performance before shipment. This supports greater batch-to-batch consistency and gives researchers confidence when integrating assay-ready microtissues ordered at different times into ongoing studies or screening programmes. This level of standardization is particularly important for repeated-dose experiments, compound screening campaigns, long-term studies and projects in which data must be compared across plates, batches, or time points.
Reduce Model-Development Time and Operational Complexity
Developing physiologically relevant 3D in vitro models in-house can delay the experiments that generate the data researchers actually need. Cell sourcing, aggregation, maturation, assay optimization, and model validation can take weeks or months before the first compound is evaluated.
Assay-ready formats reduce this operational burden. Rather than building model-production capabilities for liver, islet, and neural applications, laboratories can introduce standardized 3D InSightTM Microtissues directly into their existing workflows.
3D InsightTM Microtissues arrive pre-aggregated, quality-controlled, and ready for experimental use in automation-compatible microplates. This allows scientific teams to focus their resources on study design, compound testing, data analysis, and decision-making instead of time-consuming and resource-intensive model development.
For researchers, assay readiness is therefore more than a matter of convenience. It is a practical way to reduce complexity, shorten time to data, and apply advanced 3D biology more consistently across drug discovery programmes.
One Partner, Different Drug Discovery Applications
Across liver, pancreatic islet, and CNS research, researchers address different scientific questions but often face the same practical challenges: accessing physiologically relevant biology, reducing experimental variability, and generating reliable data that support confident drug discovery decisions.
- Liver microtissues for safety, efficacy and translational research
In liver safety and efficacy studies, researchers need models that can support a broad range of applications, including human-relevant drug-induced liver injury assessment, pharmacokinetic and metabolism studies, efficacy testing, liver disease modelling, and environmental chemical toxicity assessment.
3D InSightâ„¢ Human Liver Microtissues provide a well-established platform for DILI and translational liver research, enabling researchers to investigate compound effects in a physiologically relevant human liver model, supporting long-term studies. Complementary 3D InSightâ„¢ Beagle Dog and C57BL/6 Mouse Liver Microtissues enable direct cross-species comparison of hepatotoxicity, helping teams determine whether safety signals observed in preclinical species are likely to be relevant to humans and strengthening translational confidence.
- Standardised human pseudoislets for diabetes research
In diabetes research, conventional isolated human islets can be difficult to use consistently because of their inherent variability in size, cellular composition, purity, viability, and functional performance. 3D InSight™ Human Islet Microtissues address this challenge through standardized production. These assay-ready human pseudoislets are generated by reaggregating primary human islet cells into uniform 3D microtissues that retain key features of native islet architecture and function. They support reproducible studies of β-cell function, glucose-stimulated insulin secretion, diabetes-related disease mechanisms, and therapeutic response.
- Human neural microtissues for CNS safety assessment
In CNS safety, neurotoxicity and functional liabilities may only become apparent at later stages of drug development. Many CNS screening workflows still rely on 2D neuronal cultures, which do not fully reflect cellular interactions and network behaviour of the human brain. 3D InSightâ„¢ Human Neural Microtissues provide ready-to-use, human iPSC-derived cortical neural spheroids for scalable neurotoxicity and CNS safety assessment.
Although each model addresses a different biological question, the value for researchers is consistent: assay-ready, human-relevant 3D biology that integrates into established drug discovery workflows and supports more reliable safety, efficacy, and translational decisions.
Shipped Globally with Care- Ready for Your Assay
Assay readiness depends not only on how microtissues are produced, but also on how reliably they reach the laboratory.
InSphero’s award-winning InFloat™ Shipping System enables the global delivery of 3D InSight™ Microtissues in a temperature- and humidity-controlled environment. Buoyancy-mediated stabilization helps keep each spheroid intact and correctly positioned within the Akura™ Spheroid Microplate throughout transport.
The InFloatâ„¢ shipping system ensures viability and functionality of assay-ready microtissues during global transport.
The microtissues are shipped in optimized 3D InSightâ„¢ maintenance medium, helping preserve viability and functionality so that the models arrive ready for experimental use.
For researchers, this carefully controlled delivery process extends the value of standardized bioproduction to the point of use – supporting consistent model quality, predictable study planning, and reliable access to assay-ready 3D biology across global laboratory locations.
